Arpan Mohanty, MD
Gastroenterology · Boston, MANPI 1306166202
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $31,601 of the $34,833 with a category attached, or 90.7%. 6 manufacturers reported payments, led by Novo Nordisk at 58.3% of the total. Reporting peaked in 2024 at $22,321 and has fallen 54.9% since, to $10,063 in 2025. Among gastroenterology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $2177.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$20K
- Gilead$7K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- Madrigal Pharmaceuticals$232
- Intercept Pharmaceuticals, Inc.$118
- Kowa Research Institute, Inc.$84
Across 69 payments — averaging $5906.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Madrigal Pharmaceuticals$217K
- Takeda Pharmaceuticals U.S.A., Inc.$152K
- Intercept Pharma Europe Ltd.$33K
- AstraZeneca$6K
- Novo Nordisk AS$121
What the payments were for
- Consulting fees$31,60191%
- Travel & lodging$2,3737%
- Food & beverage$8592%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 8 | $20,297 |
| Gilead | 2 | $7,270 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $6,831 |
| Madrigal Pharmaceuticals | 2 | $232 |
| Intercept Pharmaceuticals, Inc. | 1 | $118 |
| Kowa Research Institute, Inc. | 1 | $84 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,833 in reported general payments places this provider in the 90th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 12 | $110,946 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 22 | $362 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 15 | $319 |
| Carvedilol | 18 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $118 | $110,94612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 579 gastroenterology providers in Massachusetts.
Other gastroenterology in Boston
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Carlo TraversoBoston$447K
- Tyler BerzinBoston$215K
- Marvin RyouBoston$162K
- Nneka UfereBoston$153K
- Christopher ThompsonBoston$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.